Mesoblast (NASDAQ:MESO) Raised to Buy at Maxim Group

Maxim Group upgraded shares of Mesoblast (NASDAQ:MESO) from a hold rating to a buy rating in a research report sent to investors on Tuesday, MarketBeat Ratings reports. Maxim Group currently has $12.00 price target on the stock.

Several other analysts have also recently commented on MESO. StockNews.com cut shares of Mesoblast from a hold rating to a sell rating in a research note on Wednesday, September 4th. Piper Sandler raised Mesoblast from a neutral rating to an overweight rating and lifted their target price for the stock from $4.00 to $11.00 in a report on Tuesday, July 23rd. Jefferies Financial Group raised Mesoblast from a hold rating to a buy rating in a research note on Thursday, August 29th. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Mesoblast in a research note on Thursday, August 29th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Mesoblast has a consensus rating of Moderate Buy and an average target price of $11.50.

Mesoblast Trading Up 6.3 %

Shares of MESO opened at $7.42 on Tuesday. The firm has a market cap of $847.20 million, a P/E ratio of -6.63 and a beta of 3.47. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. Mesoblast has a 1 year low of $1.61 and a 1 year high of $8.66. The company has a 50 day simple moving average of $6.59 and a two-hundred day simple moving average of $6.40.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC raised its position in Mesoblast by 50.1% during the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock valued at $34,000 after purchasing an additional 1,663 shares during the period. Lazari Capital Management Inc. boosted its stake in Mesoblast by 6.6% during the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock worth $364,000 after buying an additional 3,300 shares during the period. Chapin Davis Inc. increased its position in Mesoblast by 50.0% during the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after acquiring an additional 5,000 shares during the last quarter. Perkins Coie Trust Co bought a new position in Mesoblast during the second quarter valued at $68,000. Finally, Pine Valley Investments Ltd Liability Co bought a new stake in shares of Mesoblast in the 2nd quarter worth about $80,000. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.